2 news · updated Jul 26, 2026

IPI raises buyback

2026-07-25

Elicio Therapeutics Inc Receives 'Buy' Rating with $20 Target

Elicio Therapeutics Inc, a clinical-stage biotechnology company focusing on cancer immunotherapies, has been given a 'Buy' rating by analysts. Despite recent weak market performance, the stock is cons

TradingKey · 2026-07-25 21:40 UTC

2026-06-04

Intrepid Potash Increases Share Repurchase Authorization to $50M

Intrepid Potash has increased its share repurchase authorization to $50 million, citing improved operating performance and commitment to enhancing shareholder value.

Yahoo Finance · 2026-06-04 10:03 UTC

Media coverage (2)

Elicio Therapeutics Inc Receives 'Buy' Rating with $20 TargetTradingKey
Intrepid Potash Increases Share Repurchase Authorization to $50MYahoo Finance

IPI raises buyback

Elicio Therapeutics Inc Receives 'Buy' Rating with $20 Target

Intrepid Potash Increases Share Repurchase Authorization to $50M

Media coverage (2)

Related topics